ACUTE BIPHENOTYPIC LEUKAEMIA

ACUTE BIPHENOTYPIC LEUKAEMIA was reported 93 times

ACUTE BIPHENOTYPIC LEUKAEMIA is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 CD22-directed Immunoconjugate [EPC] 1 0.0003
1 Echinocandin Antifungal [EPC] 2 0.0002
2 Osmotic Diuretic [EPC] 1 0.0002
3 BCL-2 Inhibitor [EPC] 8 0.0001
4 Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC] 2 0.0001
5 Alkylating Drug [EPC] 20 0.0001
6 Proteasome Inhibitor [EPC] 9 0.0001
7 Topoisomerase Inhibitor [EPC] 4 0.0001
8 Azole Antifungal [EPC] 8 0.0001
9 Microtubule Inhibitor [EPC] 8 0.0000
10 Calcineurin Inhibitor Immunosuppressant [EPC] 5 0.0000
11 Nucleoside Metabolic Inhibitor [EPC] 10 0.0000
12 CD20-directed Cytolytic Antibody [EPC] 11 0.0000
13 Iron Chelator [EPC] 1 0.0000
14 Dihydropyridine Calcium Channel Blocker [EPC] 10 0.0000
15 Leukocyte Growth Factor [EPC] 4 0.0000
16 Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor [EPC] 3 0.0000
17 Corticosteroid [EPC] 33 0.0000
18 Platinum-based Drug [EPC] 7 0.0000
19 Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC] 3 0.0000
20 Nucleoside Analog Antiviral [EPC] 2 0.0000
21 General Anesthetic [EPC] 1 0.0000
22 Insulin [EPC] 1 0.0000
23 Thalidomide Analog [EPC] 11 0.0000
24 Glycopeptide Antibacterial [EPC] 1 0.0000
25 HER2/neu Receptor Antagonist [EPC] 1 0.0000
26 Dihydrofolate Reductase Inhibitor Antibacterial [EPC] 1 0.0000
27 Folate Analog Metabolic Inhibitor [EPC] 4 0.0000
28 Nonsteroidal Anti-inflammatory Drug [EPC] 11 0.0000
29 Histamine-2 Receptor Antagonist [EPC] 1 0.0000
30 Kinase Inhibitor [EPC] 4 0.0000
31 Janus Kinase Inhibitor [EPC] 1 0.0000
32 Xanthine Oxidase Inhibitor [EPC] 1 0.0000
33 Endothelin Receptor Antagonist [EPC] 1 0.0000
34 Opioid Agonist [EPC] 1 0.0000
35 Loop Diuretic [EPC] 1 0.0000
36 Interleukin-4 Receptor alpha Antagonist [EPC] 1 0.0000
37 Tumor Necrosis Factor Blocker [EPC] 1 0.0000